Foundation Medicine, Inc. (FMI)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
20.84-0.39 (-1.84%)
At close: 4:00 PM EDT
People also watch:
EPZMXLRNAGIOMGNXFPRX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open21.15
Prev Close21.23
Bid20.84 x 2500
Ask20.86 x 200
Day's Range20.79 - 21.59
52wk Range13.34 - 25.98
1y Target EstN/A
Market Cap727.89M
P/E Ratio (ttm)-8.37
BetaN/A
Volume120,125
Avg Vol (3m)228,854
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Capital Cubeyesterday

    ETF’s with exposure to Foundation Medicine, Inc. : August 29, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Foundation Medicine, Inc. Here are 5 ETF’s with the largest exposure to FMI-US. Comparing the performance and risk of Foundation Medicine, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Foundation Medicine, Inc. breached its 50 day moving average in a Bearish Manner : FMI-US : August 25, 2016
    Capital Cube5 days ago

    Foundation Medicine, Inc. breached its 50 day moving average in a Bearish Manner : FMI-US : August 25, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Foundation Medicine, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Business Wire8 days ago

    Foundation Medicine Adds New Immunotherapy Features to Its Market-Leading Products

    Foundation Medicine, Inc. today announced the addition of new clinical markers to its FoundationOne® and FoundationOne® Heme products, which are designed to enhance oncologists’ insight into potential response to immunotherapies.